BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib

JAMA Dermatology

Volumn 150, Issue 10, 2014, Pages 1079-1082

  McClenahan, Phil ^a   Lin, Lynlee L ^a   Tan, Jean Marie ^a   Flewell Smith, Ross ^a   Schaider, Helmut ^a   Jagirdar, Kasturee ^a   Atkinson, Victoria ^b   Lambie, Duncan ^a,c   Prow, Tarl W ^a   Sturm, Richard A ^a   Soyer, H Peter ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c IQ PATHOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ARTICLE; BRAF GENE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; DRUG EFFICACY; EPILUMINESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; MUTATIONAL ANALYSIS; NEVUS; PANCREAS METASTASIS; SKIN BIOPSY; SKIN PIGMENTATION; TREATMENT RESPONSE; GENETICS; MUTATION; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DERMOSCOPY; HUMANS; IMIDAZOLES; MALE; MELANOMA; MUTATION; NEVUS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS;

EID: 84908042306     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.436     Document Type: Article

References (15)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-954.
2. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20.
3. Wan PT, Garnett MJ, Roe SM, et al; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867.
4. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res. 2006;16(2):97-103.
5. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
6. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148 (10):1183-1185.
7. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448-1450.
8. Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy [published online November 7, 2013]. J Invest Dermatol. doi:10.1038/jid.2013.462.
9. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
10. Hofmann-Wellenhof R,Wolf P, Smolle J, Reimann-Weber A, Soyer HP, Kerl H. Influence of UVB therapy on dermoscopic features of acquired melanocytic nevi. J AmAcad Dermatol. 1997;37(4): 559-563.
11. Soyer HP, Lin LL, ProwTW. A plea for biobanking of all equivocal melanocytic proliferations. JAMA Dermatol. 2013;149(9):1023-1024.
12. Banan P, Lin LL, Lambie D, Prow T, Soyer HP. Effects of ex vivo skinmicrobiopsy on histopathologic diagnosis in melanocytic skin lesions. JAMA Dermatol. 2013;149(9):1107-1109.
13. Lin LL, Prow TW, Raphael AP, et al. Microbiopsy engineered forminimally invasive and suture-free sub-millimetre skin sampling. F1000 Res. 2013;2:120. doi:10.12688/f1000research.2-120.v2. http: //f1000research.com/articles/2-120/v2. Accessed February 26, 2013.
14. Tschandl P, Berghoff AS, Preusser M, et al. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One. 2013;8(7): e69639.
15. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464(7287):431-435.